Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Janes

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Biochemical Journal|July 20, 2011
Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteinsKimberly Romero Rosales, Gurpreet Singh, Kevin Wu, et al.
Science Translational Medicine|September 20, 2019
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancerMiriam Molina-Arcas, Christopher Moore, Sareena Rana, et al.
Molecular Cancer Therapeutics|July 31, 2020
Tipifarnib as a Precision Therapy for <i>HRAS</i>-Mutant Head and Neck Squamous Cell CarcinomasMara Gilardi, Zhiyong Wang, Marco Proietto, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2013
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell functionSharon Lim, Tzuen Yih Saw, Min Zhang, et al.
Nature Medicine|January 15, 2010
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMatthew R Janes, Jose J Limon, Lomon So, et al.
The Journal of Biological Chemistry|January 1, 2013
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte functionLomon So, Sung Su Yea, Jean S Oak, et al.
Nature|February 28, 2012
The translational landscape of mTOR signalling steers cancer initiation and metastasisAndrew C Hsieh, Yi Liu, Merritt P Edlind, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Biochemical Journal|July 20, 2011
Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteinsKimberly Romero Rosales, Gurpreet Singh, Kevin Wu, et al.
Science Translational Medicine|September 20, 2019
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancerMiriam Molina-Arcas, Christopher Moore, Sareena Rana, et al.
Molecular Cancer Therapeutics|July 31, 2020
Tipifarnib as a Precision Therapy for <i>HRAS</i>-Mutant Head and Neck Squamous Cell CarcinomasMara Gilardi, Zhiyong Wang, Marco Proietto, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2013
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell functionSharon Lim, Tzuen Yih Saw, Min Zhang, et al.
Nature Medicine|January 15, 2010
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMatthew R Janes, Jose J Limon, Lomon So, et al.
The Journal of Biological Chemistry|January 1, 2013
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte functionLomon So, Sung Su Yea, Jean S Oak, et al.
Nature|February 28, 2012
The translational landscape of mTOR signalling steers cancer initiation and metastasisAndrew C Hsieh, Yi Liu, Merritt P Edlind, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Pageof 3